Ra Capital Management, L.P. Buys 124,893 Shares of Artiva Biotherapeutics (NASDAQ:ARTV) Stock

by · The Markets Daily

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV – Get Free Report) Director Ra Capital Management, L.P. bought 124,893 shares of the firm’s stock in a transaction that occurred on Tuesday, June 16th. The shares were purchased at an average cost of $8.89 per share, with a total value of $1,110,298.77. Following the transaction, the director directly owned 16,763,043 shares of the company’s stock, valued at $149,023,452.27. The trade was a 0.75% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website.

Ra Capital Management, L.P. also recently made the following trade(s):

  • On Monday, June 15th, Ra Capital Management, L.P. bought 15,414 shares of Artiva Biotherapeutics stock. The shares were purchased at an average cost of $8.99 per share, with a total value of $138,571.86.
  • On Friday, June 12th, Ra Capital Management, L.P. bought 391,019 shares of Artiva Biotherapeutics stock. The shares were purchased at an average cost of $8.57 per share, with a total value of $3,351,032.83.
  • On Thursday, June 11th, Ra Capital Management, L.P. bought 548,580 shares of Artiva Biotherapeutics stock. The shares were purchased at an average cost of $7.91 per share, with a total value of $4,339,267.80.
  • On Wednesday, June 10th, Ra Capital Management, L.P. bought 103 shares of Artiva Biotherapeutics stock. The shares were purchased at an average cost of $7.00 per share, with a total value of $721.00.
  • On Tuesday, June 9th, Ra Capital Management, L.P. bought 479,039 shares of Artiva Biotherapeutics stock. The shares were purchased at an average cost of $6.91 per share, with a total value of $3,310,159.49.
  • On Monday, May 11th, Ra Capital Management, L.P. bought 6,510,416 shares of Artiva Biotherapeutics stock. The shares were purchased at an average cost of $11.52 per share, with a total value of $74,999,992.32.

Artiva Biotherapeutics Stock Performance

NASDAQ:ARTV traded down $0.27 during midday trading on Tuesday, reaching $8.91. 780,946 shares of the stock traded hands, compared to its average volume of 355,699. Artiva Biotherapeutics, Inc. has a 12-month low of $1.47 and a 12-month high of $14.53. The business has a 50-day moving average of $8.98 and a two-hundred day moving average of $6.20. The stock has a market capitalization of $220.26 million, a PE ratio of -2.52 and a beta of 2.40.

Artiva Biotherapeutics (NASDAQ:ARTV – Get Free Report) last issued its quarterly earnings results on Friday, May 8th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.07). Research analysts anticipate that Artiva Biotherapeutics, Inc. will post -2.45 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the stock. Wall Street Zen lowered shares of Artiva Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, May 17th. HC Wainwright raised their price target on shares of Artiva Biotherapeutics from $15.00 to $35.00 and gave the stock a “buy” rating in a research note on Friday, May 8th. Wedbush lifted their target price on shares of Artiva Biotherapeutics from $23.00 to $40.00 and gave the stock an “outperform” rating in a research note on Monday, May 11th. Cantor Fitzgerald reissued an “overweight” rating on shares of Artiva Biotherapeutics in a research note on Tuesday, May 26th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $41.00 price target on shares of Artiva Biotherapeutics in a research note on Monday, June 8th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $39.00.

View Our Latest Analysis on Artiva Biotherapeutics

Institutional Investors Weigh In On Artiva Biotherapeutics

Large investors have recently added to or reduced their stakes in the business. Prelude Capital Management LLC purchased a new stake in Artiva Biotherapeutics during the 3rd quarter worth approximately $41,000. Bank of America Corp DE boosted its holdings in shares of Artiva Biotherapeutics by 225.8% in the 3rd quarter. Bank of America Corp DE now owns 16,145 shares of the company’s stock valued at $46,000 after buying an additional 11,190 shares in the last quarter. Dimensional Fund Advisors LP acquired a new position in shares of Artiva Biotherapeutics in the 1st quarter valued at $131,000. OMERS ADMINISTRATION Corp acquired a new stake in Artiva Biotherapeutics during the 4th quarter worth $91,000. Finally, Sanctuary Advisors LLC acquired a new stake in Artiva Biotherapeutics during the 1st quarter worth $139,000.

About Artiva Biotherapeutics

(Get Free Report)

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.

Recommended Stories